Boditech Med said Wednesday that it has acquired a 3.03 percent stake in 4TEEN4 Pharmaceuticals GmbH (4TEEN4), a German company focusing on developing therapeutics and diagnostic biomarkers for treating cardiogenic shock.

Along with the equity investment, Boditech Med has entered into a license agreement to develop and market diagnostic biomarker products owned by 4TEEN4.

According to Boditech Med, 4TEEN4 is developing procizumab, a DPP3 inhibitor, to provide a next-generation therapy to prevent the occurrence and death of myocardial shock. The DPP3 biomarker, developed and owned by 4TEEN4, is used to predict and monitor cardiogenic shock in patients with acute coronary syndrome (ACS) and acute heart failure.

DPP3 is the leading cause of cardiogenic shock, affecting more than 4 million patients annually worldwide. The global demand for DPP3 point-of-care products is estimated to be more than 50 million units annually.

"Last year, cardiovascular disease-related products drove the growth of Boditech Med, with sales increasing by more than 40 percent year-on-year," Boditech Med CEO Choi Eui-yeol said. "This equity investment in 4TEEN4 significantly strengthens our all-around cooperation in the cardiovascular disease sector. We plan to launch our DPP3 diagnostic this year, contributing to our revenue growth from 2025 onwards."